Drug Trial News RSS Feed - Drug Trial News

NIH-supported first HIV vaccine efficacy study begins in South Africa

NIH-supported first HIV vaccine efficacy study begins in South Africa

The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. [More]
Drug combination therapy delays progression of advanced breast cancer without side effects, study shows

Drug combination therapy delays progression of advanced breast cancer without side effects, study shows

Building on earlier clinical trials, UCLA researchers have confirmed that the "breakthrough" drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone. [More]
NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

NYU Langone Medical Center will lead a five-year, 60-center clinical trial to evaluate new treatment protocols for herpes zoster ophthalmicus (HZO), a form of shingles that can seriously and permanently affect the eye. [More]
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab). [More]
Clinical study to test safety and ability of investigational Zika vaccine candidate begins

Clinical study to test safety and ability of investigational Zika vaccine candidate begins

The first of five early stage clinical trials to test the safety and ability of an investigational Zika vaccine candidate called the Zika Purified Inactivated Virus (ZPIV) vaccine to generate an immune system response has begun at the Walter Reed Army Institute of Research Clinical Trial Center in Silver Spring, Maryland. [More]
Sanford opens new immunotherapy study on colorectal cancer

Sanford opens new immunotherapy study on colorectal cancer

Sanford Health has opened another clinical trial exploring the power of the body's immune system to fight cancer. [More]
New clinical study to examine novel dietary approach for TNBC

New clinical study to examine novel dietary approach for TNBC

A new clinical trial for women with clinically aggressive triple-negative breast cancer (TNBC) will test a novel theory: Will a diet low in an essential nutrient make TNBC cells more vulnerable to cell killing by a new cancer drug? [More]
BetterYou’s oral spray effective in correcting vitamin D insufficiency in athletes, study shows

BetterYou’s oral spray effective in correcting vitamin D insufficiency in athletes, study shows

The findings of a study by Ulster University in conjunction with health pioneers BetterYou, have confirmed existing literature showing how athletes, despite spending an above average amount of time outdoors, are still at risk of vitamin D deficiency. [More]
Natural compound found in red wine can lower testosterone levels in women with PCOS

Natural compound found in red wine can lower testosterone levels in women with PCOS

Resveratrol—a natural compound found in red wine and grapes—can help address a hormone imbalance in women with polycystic ovary syndrome (PCOS), a leading cause of infertility in women, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Study to investigate clinical impact of new treatment for HFrEF patients

Study to investigate clinical impact of new treatment for HFrEF patients

The academic partners in the VerICiguaT GlObal Study in Subjects with Heart Failure with Reduced EjectIon FrAction are pleased to announce that patient enrollment has begun. [More]
Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen [More]
Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen. [More]
PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine. [More]
Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen. [More]
Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen. [More]
Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen. [More]
UAB researchers launch first drug study to prevent onset of epilepsy in children with TSC

UAB researchers launch first drug study to prevent onset of epilepsy in children with TSC

Researchers at the University of Alabama at Birmingham have launched the first drug study aimed at preventing or delaying the onset of epilepsy in children with a genetic condition known as tuberous sclerosis complex. [More]
GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease. [More]
ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease. [More]
Clinical study to test efficacy of different formulations of flu vaccine in heart failure patients

Clinical study to test efficacy of different formulations of flu vaccine in heart failure patients

Heart disease patients enrolled in a clinical trial - designed to test whether a stronger dose of the influenza vaccine can prevent death or hospitalization due to a heart attack, heart failure, stroke or pneumonia - have begun receiving their first flu shots in Toronto and Boston. [More]
Advertisement
Advertisement